Cancer clinical trials in the region Auvergne-Rhône-Alpes

326 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 1 / Phase 2 Liver and bile duct cancer #NCT06923761 #2023-504845-30-00

[EMITT-1] Essai de ciblage de l'immunopeptidome médié par ERAP - 1

Hepatocellular carcinoma Locally Advanced Metastatic Unhealthy A 1 2 Immunotherapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Grey Wolf Therapeutics

Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06923761 #2023-504845-30-00

[EMITT-1] Essai de ciblage de l'immunopeptidome médié par ERAP - 1

Locally Advanced Metastatic 1 2 3 or more

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Grey Wolf Therapeutics

Phase 1 / Phase 2 Lung cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer #NCT06923761 #2023-504845-30-00

[EMITT-1] Essai de ciblage de l'immunopeptidome médié par ERAP - 1

NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma Locally Advanced Metastatic TMB 1 2 Immunotherapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Grey Wolf Therapeutics

Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04752722 #2024-512900-20-00

[LEGEND] EG-70 chez les patients atteints de cancer de la vessie non invasif réfractaire au BCG et à haut risque traités incomplètement par le BCG ou naïfs au BCG

Non-invasive bladder cancer Urothelial carcinoma Localized None 1 Systemic Treatment-Naive Immunotherapy

Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon)

enGene, Inc.

Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04752722 #2024-512900-20-00

[LEGEND] EG-70 chez les patients atteints de cancer de la vessie non invasif réfractaire au BCG et à haut risque traités incomplètement par le BCG ou naïfs au BCG

Non-invasive bladder cancer Urothelial carcinoma Localized 2 3 or more

Systemic Treatment-Naive

Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon)

enGene, Inc.

Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06934538 #2024-512011-45-00

[BreAK CRC] Premier essai chez l'humain du STC-1010, une immunothérapie, chez des patients atteints d'un cancer colorectal localement avancé ou métastatique non résécable

Adenocarcinoma Locally Advanced Metastatic KRAS G12C KRAS non G12C MSS/pMMR None Systemic Treatment-Naive

BRAF Immunotherapy

Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon)

Brenus Pharma

Phase 1 / Phase 2 Endometrial cancer #NCT03564340 #2024-510783-23-00

Étude de REGN4018 administré seul ou en association avec le CEMIPLIMAB chez des patients adultes atteints d'un cancer de l'ovaire récurrent ou d'autres cancers MUC16+

Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy

Systemic Treatment-Naive

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)

Regeneron Pharmaceuticals

Phase 1 / Phase 2 CLL & Richter's syndrome #NCT04623541 #2023-504828-25-00

[EPCORE™ CLL-1] Étude d'innocuité et d'efficacité de l'EPCORITAMAB chez des sujets atteints de leucémie lymphoïde chronique récidivante/réfractaire et du syndrome de Richter

CLL (Chronic Lymphocytic Leukemia) None Systemic Treatment-Naive

Bispecific T-cell engager antibodies Allogeneic stem cell transplant

Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)

Genmab

Phase 1 / Phase 2 CLL & Richter's syndrome #NCT04623541 #2023-504828-25-00

[EPCORE™ CLL-1] Étude d'innocuité et d'efficacité de l'EPCORITAMAB chez des sujets atteints de leucémie lymphoïde chronique récidivante/réfractaire et du syndrome de Richter

CLL (Chronic Lymphocytic Leukemia) 1 2 3 or more

Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant

Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)

Genmab

Phase 1 / Phase 2 Lymphoma #NCT04623541 #2023-504828-25-00

[EPCORE™ CLL-1] Étude d'innocuité et d'efficacité de l'EPCORITAMAB chez des sujets atteints de leucémie lymphoïde chronique récidivante/réfractaire et du syndrome de Richter

B cell lymphoma Lymphocytic lymphoma CD20 None Systemic Treatment-Naive

Bispecific T-cell engager antibodies Allogeneic stem cell transplant

Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)

Genmab